Amarin Corp Ads (AMRN) |
|
4.93 0.04 (0.82%)
|
06-18 08:11 |
|
Open: |
4.89 |
Pre. Close: |
4.89 |
|
High:
|
4.98 |
Low:
|
4.83 |
|
Volume:
|
2,423,652 |
Market Cap:
|
1,946M |
|
|
|
|
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.982 - 5.007 |
5.007 - 5.032 |
|
Low:
|
4.773 - 4.798 |
4.798 - 4.824 |
|
Close:
|
4.889 - 4.929 |
4.929 - 4.97 |
|
Technical analysis |
as of: 2021-06-17 4:42:03 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.91 One year: 6.90 |
| Support: |
Support1: 4.50 Support2: 4.16 |
| Resistance: |
Resistance1: 5.06 Resistance2: 5.91 |
| Pivot: |
4.77 |
| Moving Average: |
MA(5): 4.94 MA(20): 4.70
MA(100): 5.88  MA(250): 5.67 |
| MACD: |
MACD(12,26): 0.04 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 79.16 %D(3): 83.35 |
| RSI: |
RSI(14): 56.10 |
| 52-week: |
High: 9.25 Low: 3.36 Change(%): -28.7 |
| Average Vol(K): |
3-Month: 419003 10-Days: 270406 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.AMRN has closed below upper band by 26.5%. Bollinger Bands are 54.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to AMRN's normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 29 Apr 2021
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19 - Yahoo Finance
Mon, 26 Apr 2021
Is AMRN Stock A Buy or Sell? - Yahoo Finance
Thu, 08 Apr 2021
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 43% Below Their Intrinsic Value Estimate - Yahoo Finance
Tue, 09 Mar 2021
Did Amarin Corporation plc (NASDAQ:AMRN) Insiders Buy Up More Shares? - Yahoo Finance
Wed, 17 Feb 2021
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021 - Yahoo Finance
Fri, 08 Jan 2021
Amarin Corporation plc's (NASDAQ:AMRN) About To Shift From Loss To Profit - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
395 |
| Shares Float (M) |
358 |
|
% Held by Insiders
|
1.18 |
|
% Held by Institutions
|
38.97 |
|
Shares Short (K)
|
26,000 |
|
Shares Short P. Month (K)
|
21,980 |
Stock Financials |
|
EPS
|
0.002 |
|
EPS Est This Year
|
-0.210 |
|
EPS Est Next Year
|
-0.060 |
|
Book Value (p.s.)
|
1.610 |
|
Profit Margin
|
0.15 |
|
Operating Margin
|
0.51 |
|
Return on Assets (ttm)
|
0.2 |
|
Return on Equity (ttm)
|
0.2 |
|
Qtrly Rev. Growth
|
-8.3 |
|
Gross Profit (p.s.)
|
1.223 |
|
Sales Per Share
|
1.523 |
|
EBITDA (p.s.)
|
0.013 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-45 |
|
Levered Free Cash Flow (M)
|
-37 |
Stock Valuations |
|
PE Ratio
|
2465.00 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.06 |
|
Price to Sales
|
3.24 |
|
Price to Cash Flow
|
-43.65 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
